Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONCT 216

Next Previous
Drug Profile

ONCT 216

Alternative Names: I-036; SPH-8216; TK-216

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tokalas, Inc.
  • Developer Oncternal Therapeutics, Inc.; Shanghai Pharmaceuticals Holding
  • Class Antineoplastics; Chlorinated hydrocarbons; Cyclopropanes; Indoles; Small molecules
  • Mechanism of Action Proto-oncogene protein c-ets inhibitors; Proto-oncogene protein c-fli-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ewing's sarcoma
  • No development reported Acute myeloid leukaemia; Diffuse large B cell lymphoma; Glioblastoma; Prostate cancer

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA (Parenteral)
  • 28 Mar 2025 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)
  • 05 Feb 2025 Shanghai Pharmaceuticals Holding completes a phase-II trial in Ewing's Sarcoma (Combination therapy, Second-line therapy or greater, In adolescents, In adults, In the elderly) in China (IV) (NCT05046314)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top